174 related articles for article (PubMed ID: 32737156)
21. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
22. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
23. Characterization of multiple first exons in murine prolactin receptor gene and the effect of prolactin on their expression in the choroid plexus.
Tabata H; Kobayashi M; Ikeda JH; Nakao N; Saito TR; Tanaka M
J Mol Endocrinol; 2012 Apr; 48(2):169-76. PubMed ID: 22294444
[TBL] [Abstract][Full Text] [Related]
24. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
25. Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist.
Cui H; Ma YZ; Wang Y; Song M; Zhang H
Int J Biol Macromol; 2017 Feb; 95():1223-1227. PubMed ID: 27829125
[TBL] [Abstract][Full Text] [Related]
26. The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females.
Chen Y; Moutal A; Navratilova E; Kopruszinski C; Yue X; Ikegami M; Chow M; Kanazawa I; Bellampalli SS; Xie J; Patwardhan A; Rice K; Fields H; Akopian A; Neugebauer V; Dodick D; Khanna R; Porreca F
Sci Transl Med; 2020 Feb; 12(529):. PubMed ID: 32024801
[TBL] [Abstract][Full Text] [Related]
27. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
[TBL] [Abstract][Full Text] [Related]
28. Prolactin stimulates cell migration and invasion by human trophoblast in vitro.
Stefanoska I; Jovanović Krivokuća M; Vasilijić S; Ćujić D; Vićovac L
Placenta; 2013 Sep; 34(9):775-83. PubMed ID: 23849393
[TBL] [Abstract][Full Text] [Related]
29. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
30. Expression of autocrine prolactin and the short isoform of prolactin receptor are associated with inflammatory response and apoptosis in monocytes stimulated with Mycobacterium bovis proteins.
López-Rincón G; Mancilla R; Pereira-Suárez AL; Martínez-Neri PA; Ochoa-Zarzosa A; Muñoz-Valle JF; Estrada-Chávez C
Exp Mol Pathol; 2015 Jun; 98(3):517-26. PubMed ID: 25797370
[TBL] [Abstract][Full Text] [Related]
31. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
Langenheim JF; Chen WY
Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
[TBL] [Abstract][Full Text] [Related]
32. Different intracellular signalling pathways triggered by an anti-prolactin receptor (PRLR) antibody: Implication for a signal-specific PRLR agonist.
Kan QE; Su Y; Yang H; Man H
Int J Biol Macromol; 2016 Jan; 82():892-7. PubMed ID: 26526176
[TBL] [Abstract][Full Text] [Related]
33. A short form of the prolactin (PRL) receptor is able to rescue mammopoiesis in heterozygous PRL receptor mice.
Binart N; Imbert-Bollore P; Baran N; Viglietta C; Kelly PA
Mol Endocrinol; 2003 Jun; 17(6):1066-74. PubMed ID: 12624115
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain.
Kline JB; Rycyzyn MA; Clevenger CV
Mol Endocrinol; 2002 Oct; 16(10):2310-22. PubMed ID: 12351696
[TBL] [Abstract][Full Text] [Related]
35. The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter.
Berlanga JJ; Garcia-Ruiz JP; Perrot-Applanat M; Kelly PA; Edery M
Mol Endocrinol; 1997 Sep; 11(10):1449-57. PubMed ID: 9280060
[TBL] [Abstract][Full Text] [Related]
36. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
37. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
39. Prolactin improves hepatic steatosis via CD36 pathway.
Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
[TBL] [Abstract][Full Text] [Related]
40. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
